

President & CEO

Hiroshi Tomiyama, Ph.D.

Qualifications

1990: Radiation Protection Officer

1992: Bachelor of Science in Pharmacy, Pharmacist

1997: Ph.D. in Pharmaceutical Science

Work Experiences

2017-2019: Part-time Lecturer (Concurrent), Medicinal Chemistry,
Graduate School & Faculty of Pharmaceutical Sciences, Chiba University, Japan

Lecture content: “A Medicinal Chemist’s Toolbox”

Training to identify metabolic sites of molecules at a glance;

Differences between theoretical organic reaction mechanisms and in reality.

2014 - current: President & CEO at Kotobuki Pharma

2000: Joined with Kotobuki Pharma

1997-1999: Postdoctoral Researcher, under the supervision of Professor Robert J. Linhardt,
Division of Medicinal and Natural Products Chemistry (MNPC), College of Pharmacy,
The University of Iowa, USA

Research subject; The synthesis of catabolically stable C-glycoside analogue of cancer carbohydrate antigen toward cancer vaccine development.

Awards

Medicinal Chemistry (Med. Chem.);

2015: Breakthrough Award, Division of Medicinal Chemistry, Pharmaceutical Society of Japan

Title: Discovery of ipragliflozin (Suglat®): A potent and selective sodium glucose co transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

Pharmaceutical Engineering (Pharm. Eng.);

2022: The 21st Century research grants, Nagano Pharmaceutical Association

Title: The development of easy to split with fingers and easy to swallow of “KAWARA” Orally Disintegrating tablets ®